Beximco Pharma debuts in Cambodia market
As part of its growth strategy, Bangladesh's pharmaceutical giant, Beximco Pharmaceuticals began exporting its drugs to Cambodia.
bdnews24.com News Service
bdnews24.com
Published :
15 Jul 2006, 06:00 PM
Updated :
17 Aug 2022, 06:26 PM
Dhaka, July 16 (BDNEWS) - As part of its growth strategy, Bangladesh's pharmaceutical giant, Beximco Pharmaceuticals began exporting its drugs to Cambodia.
The first export consignment comprising of six products of BPL has already been shipped to Cambodia in the first week of this month, said a press release in Dhaka Sunday.
The drugs include Neoceptin-R 150mg Tablet (Ranitidine), Omastin 150mg Capsule (Fluconazole), Pretin 10mg Tablet (Loratadine), Yamadin 20mg Tablet (Famotidine), Yamadin 40mg Tablet (Famotidine) and Neopril 5mg Tablet (Lisinopril).
Commenting on export to Cambodia, Beximco Pharma chief executive officer Nazmul Hassan said: The Doha Declaration of WTO/ TRIPS has exempted Bangladesh from implementing pharmaceutical patent up to 2016.
"This has opened up new avenues for us to export patented pharmaceuticals to the Least Developed Countries (LDCs). And to take full advantage of these export opportunities, at the very right time, BPL has entered Cambodia -- an LDC," he said.
To get an overwhelming response in this LDC, Beximco Pharma has also launched formal marketing and promotional campaigns of its products in Cambodia with Vimpex Ltd -- BPL's partner in Cambodia.
Vimpex Ltd will be responsible for registration, import, sales and distribution of BPL products in Cambodia. Beximco Pharma has also recruited field sales forces to promote and sell BPL products in Cambodia.
Nazmul said that Cambodia is the fourth ASEAN country after Singapore, Vietnam and Myanmar, where BPL has launched its operation. "Being an import based country for pharmaceuticals, Cambodia is an ideal overseas market for BPL to have a sustainable and steady growth and expand its business and market shares."
BPL has also applied for the registration of 28 new products in Cambodia. Most of these 28 new products are either patented products or high tech specialised and 'difficult-to-manufacture' products.
Beximco Pharma, a sister concern of Beximco Group, manufactures and markets its own 'branded generics' for almost all diseases.
BDNEWS/1834 hrs